All In Biotech

Drug Trial Radar · NCT05688215

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

A Pilot Study of Zimberelimab and Quemliclustat Combination With Chemotherapy in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

141

Planned (sponsor's estimate)

Start

Mar 7, 2023

Primary completion

Dec 31, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Jonsson Comprehensive Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Arcus Biosciences, Inc.; Congressionally Directed Medical Research Programs
First posted
Jan 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/II study tests how well zimberelimab and quemliclustat work in combination with chemotherapy (mFOLFIRINOX) in treating patients pancreatic adenocarcinoma that may or may not be able to be removed by surgery (borderline resectable) or that has spread to nearby tissue or lymph nodes (locally advanced). Immunotherapy with monoclonal antibodies, such as zimberelimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Quemliclustat acts as a blocker for adenosine. Adenosine is a chemical produced in the body that can lead to a decrease in the immune system's response towards cancer. Quemliclustat has the potential to decrease the amount of adenosine, allowing the immune system to recognize and act against the cancer. Chemotherapy drugs, such as oxaliplatin, irinotecan, leucovorin, and fluorouracil, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy in combination with zimberelimab and quemliclustat may kill more cancer cells than chemotherapy alone.

Conditions

  • Borderline Resectable Pancreatic Adenocarcinoma
  • Locally Advanced Pancreatic Ductal Adenocarcinoma

Interventions

  • Biospecimen CollectionProcedure

    Undergo collection of blood and tissue samples

  • Computed TomographyProcedure

    Undergo a CT scan

  • Core BiopsyProcedure

    Undergo core biopsy

  • FluorouracilDrug

    Given IV

  • IrinotecanDrug

    Given IV

  • LeucovorinDrug

    Given IV

  • Leucovorin CalciumDrug

    Given IV

  • OxaliplatinDrug

    Given IV

  • QuemliclustatDrug

    Given intravenously (IV)

  • ZimberelimabDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (BPRC Cohort)Time frame: From baseline measurement to 90 days after the last dose of study treatment.
  2. Resection rate (BPRC Cohort)Time frame: Up to 2 years
  3. Progression free survival (PFS) (LAPC Cohort)Time frame: Up to 2 years
  4. Number of participants who develop clinically relevant pancreatic fistula (BPRC Cohort)Time frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yonemoto,Lisa

    Los Angeles, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.